Cyclobenzaprine Dosing
The recommended starting dose of cyclobenzaprine is 5 mg three times daily, which may be increased to 10 mg three times daily based on individual patient response, with treatment duration limited to 2-3 weeks. 1
Standard Dosing Regimen
For most patients:
- Initial dose: 5 mg orally three times daily
- Titration: May increase to 10 mg three times daily if needed
- Maximum duration: 2-3 weeks of continuous use 1
The FDA-approved labeling explicitly states this dosing schedule, with the 5 mg dose serving as the appropriate starting point for the majority of patients. Clinical trials have demonstrated that 5 mg three times daily is as effective as 10 mg three times daily for acute musculoskeletal spasm, while producing significantly less sedation 2.
Special Populations Requiring Dose Adjustment
Elderly patients (≥65 years):
- Start at 5 mg three times daily and titrate slowly upward only if clearly needed
- Plasma concentrations are approximately 1.7-fold higher in elderly patients compared to younger adults
- Elderly males show the highest increase (2.4-fold), while elderly females show more modest increases (1.2-fold) 1
- Higher risk for CNS adverse events (hallucinations, confusion), cardiac events, and falls 1
Hepatically impaired patients:
- Start at 5 mg three times daily with slow upward titration for mild impairment
- Both AUC and Cmax are approximately double in patients with hepatic impairment
- Not recommended for moderate to severe hepatic impairment due to lack of safety data 1
Clinical Context and Evidence
The evidence supporting lower-dose initiation is robust. Two large placebo-controlled trials (n=1,405) demonstrated that cyclobenzaprine 5 mg three times daily produced significantly higher efficacy scores than placebo on all primary measures (patient-rated global impression of change, medication helpfulness, and relief from pain; P≤0.001), with onset of relief apparent within 3-4 doses 2. Importantly, the 2.5 mg three times daily dose was not significantly more effective than placebo, establishing 5 mg as the minimum effective dose 2.
Regarding the 10 mg dose: While 10 mg three times daily is FDA-approved and effective, it offers no additional efficacy benefit over 5 mg three times daily but produces significantly more sedation and other adverse effects 2. The number needed to harm approximates the number needed to treat at higher conventional doses.
Duration of Treatment
Treatment should not exceed 2-3 weeks for acute musculoskeletal conditions 1. This limitation is based on the approved indication for acute painful musculoskeletal conditions. With long-term use, patients may experience withdrawal symptoms (malaise, nausea, headache) lasting 2-4 days after discontinuation, though these are not life-threatening. If discontinuation is needed after prolonged use, taper over 2-3 weeks to prevent withdrawal symptoms 3.
Perioperative Management
Hold cyclobenzaprine on the day of surgery 3. The drug has potential interactions with sedatives and anesthetic agents due to its anticholinergic effects and can cause norepinephrine potentiation. If time permits before elective procedures, consider tapering off or switching to an alternative agent 3.
Important Drug Interactions and Contraindications
- Contraindicated with MAO inhibitors: Risk of serotonin syndrome; do not use concurrently or within 14 days of MAO inhibitor discontinuation 1
- Caution with serotonergic drugs: SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, and verapamil increase serotonin syndrome risk 1
- Enhances CNS depression: Additive effects with alcohol, barbiturates, and other CNS depressants 1
Common Adverse Effects
The most frequent adverse effects are dose-related:
- Somnolence (most common)
- Dry mouth
- Dizziness
- Confusion, drowsiness, constipation, urinary retention (anticholinergic effects) 3
In hospitalized elderly patients (≥65 years), use of 10 mg versus 5 mg cyclobenzaprine was associated with 32.7% longer hospital length of stay and significantly greater need for injectable antipsychotics or benzodiazepines, underscoring the importance of lower dosing in this population 4.
Alternative Formulations
A sublingual formulation (TNX-102 SL/Tonmya) was FDA-approved in 2025 specifically for fibromyalgia at a bedtime dose of 2.8 mg for 2 weeks, then 5.6 mg thereafter 5, 6, 7. This formulation has a distinct pharmacokinetic profile and indication separate from oral cyclobenzaprine for acute musculoskeletal spasm.